Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
AP NewsAugust 27, 2026
Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively
Where this sits on TrendsMap
This story hasn’t been tied to a specific state or province yet — it sits in our United States coverage. We hold 2152 politics stories in total, and 231 from AP News.
This is a summary of reporting by AP News. Read the full story at the source.
Read full storyPredictions (0)
No predictions yet on this story — be the first to start one.
Comments (0)
GU
posting as a guest
Create a free account to comment under your own name and earn Pulse.